NCTN - Network Lead Academic Participating Site: USC

摘要 南加州大学诺里斯综合癌症中心首次参加了 SWOG成立于1987年，最初于1992年获得资助。这一五年赠款周期已经增加， 行政和学术参与，保持高临床和相关试验 进入，与现有的SWOG资金和南加州大学增加的资源相称。主要 南加州大学团队的重点是：（a）在NTCN中提供领导， 有效地进行临床试验，评估新方案的安全性和有效性，或 修改现有方案;（B）在生物标志物开发和 将新技术整合到NCTN试验中，利用系统方法， 采集、处理和储存血液、正常组织、新鲜或冷冻肿瘤组织和其他 用于分子和药理学研究的相关生物样品;以及（c）评估癌症 特殊患者人群的治疗方案，如罕见癌症、老年人和少数民族 少数群体南加州大学的研究人员不仅为SWOG试验做出了广泛的贡献， 展示了行政/学术领导力，促进了特定主题的翻译 对SWOG的调查最近的NCTN试验，如SWOG/ALLIANCE 80405和S1401 转移性结直肠癌和前列腺癌的特征， 了解两种癌症的分子亚型和特征，整合切割 包括NGS检测和单细胞分子分类在内的前沿技术。USC UG1 成员在NCI工作队和指导委员会中发挥积极作用。在其 致力于癌症临床研究，南加州大学已成功地指导年轻的研究人员 通过UM 1职业发展奖，项目团队奖学金和SWOG Young 调查员奖。南加州大学扩大了其机构培训和指导能力。 最后，作为网络领先的学术参与网站，南加州大学将继续带来独特的 NCI国家临床试验网络的优势，这得益于其在招募 少数人参加临床试验，患上罕见癌症，如胆管癌和膀胱癌，以及 建立了临床研究基础设施。

ABSTRACT The USC Norris Comprehensive Cancer Center first participated in the research activities of SWOG in 1987 and was initially funded in 1992. This five-year grant cycle has had increased administrative and academic participation, with maintenance of high clinical and correlative trial entry, commensurate with available SWOG funding and added resources from USC. The major emphases of the USC team are (a) to provide leadership across the NTCN to design and efficiently perform clinical trials evaluating the safety and efficacy of novel regimens or modifications of existing regimens; (b) to provide leadership in biomarker development and in integration of new technologies into NCTN trials, taking advantage of a systematic approach to collection, processing, and storage of blood, normal tissue, fresh or frozen tumor tissue, and other relevant biologic samples for molecular and pharmacologic studies; and (c) to evaluate cancer treatment regimens in special patient populations, such as rare cancers, the elderly and ethnic minorities. USC investigators have not only contributed extensively to SWOG trials but have demonstrated administrative/academic leadership, facilitating the translation of specific themes of investigation to SWOG. Recent NCTN trials such as SWOG/ALLIANCE 80405 and S1401 characterizing metastatic colorectal and prostate cancer has significant increased the understanding of molecular subtyping and characterization of both cancers integrating cutting edge technologies including NGS testing and single cell molecular classification. USC UG1 members are playing an active role in NCI task forces and steering committees. As part of its dedication to cancer clinical research, USC has been successful in mentoring young investigators through the UM1 Career Development Awards, Project Team Memberships and SWOG Young Investigator Awards. USC has expanded its institutional training and mentoring capabilities. Lastly, as a Network Lead Academic Participating Site, USC will continue to bring unique strengths to the NCI National Clinical Trials Network thanks to its strength in recruitment of minorities to clinical trials, accrual to rare cancers such as biliary and bladder cancers, and a well- developed clinical research infrastructure.